Sweden leading in advanced therapies in 2030

Advanced therapy drugs, i.e. gene therapies, cell therapies or tissue engineering products, enable effective treatments and in some cases cures for a number of disease states. In order for these opportunities to better benefit Swedish healthcare and patients, the challenges that currently slow down development need to be resolved.

The innovation environment brings together actors from healthcare, business, authorities, academia and patient representatives who work together in different groupings and contexts to solve the obstacles that exist today. Through a long-term renewal of the innovation system, Sweden will become a leader in the development and commercialization of advanced therapy drugs, as well as making valuable advanced therapies available to patients in healthcare.

The path towards the vision goes via activities and efforts aimed at one or more of the following five sub-goals that represent different perspectives and identified challenges:

1. Increased coordination and consolidation of power in Sweden, as well as increased internationalisation
2. Improved conditions for development and commercialization of advanced therapies in Sweden
3. Clear and coordinated processes for the development and making available of advanced therapies in Swedish healthcare.
4. Increased knowledge to secure future skills needs
5. Organization for Sustainability

The innovation environment is run by a core team of seven dedicated people with complementary skills and perspectives and different areas of responsibility. The core team initiates and coordinates activities and efforts aimed at the various sub-goals. The work is largely based on dialogue and cooperation with other existing initiatives, organizations and structures in the area. The form of collaboration strives to be inclusive and flexible; it is not necessary to be a formal party in the environment to participate in and influence the work.